Skip to main content

Human Toxoplasma gondii infection in Nigeria: a systematic review and meta-analysis of data published between 1960 and 2019



Over 70% of the worlds’ population is infected by Toxoplasma gondii; a pathogen capable of causing cerebral toxoplasmosis in HIV patients and neonatal complications like miscarriage, chorioretinitis, hydrocephalus, cerebral calcification and foetal death in the third trimester of pregnancy. In spite of this, the burden of this zoonotic pathogen is poorly understood in Nigeria. The aim of the present study therefore, is to determine the burden of T. gondii among normal individuals, HIV patients and pregnant women as well as the distribution of the infection across Nigeria.


Using the PRISMA guidelines, we conducted a systematic review and meta-analysis of data retrieved from six electronic databases (AJOL, Google Scholar, PubMed, Scopus, Science Direct and Web of Science). Pooled prevalence (PP) and heterogeneity were determined by the random-effects model and the Cochran’s Q-test respectively. The quality of each study and publication bias were assessed by the 9 point Joanna Briggs Institute Critical Appraisal Instrument and the Egger’s regression asymmetry test respectively, while the robustness of a pooled estimate was tested by the single study omission analysis.


Exactly 5834 of the 16,230 individuals examined for T. gondii infection by 50 studies across 17 Nigerian States were positive for the infection. Overall PP was 32.92% (95% CI: 27.89, 38.37), with a range of 14.41% (95% CI: 5.32, 33.54) to 86.82% (95% CI: 66.13, 95.69) across sub-groups. Pooled prevalence was significantly higher (p < 0.001) among pregnant women (40.25%; 95% CI: 33.19, 47.73) and HIV patients (31.68, 95% CI: 20.53, 45.41) than normal individuals (23.32, 95% CI: 17.25, 30.75). T. gondii prevalence declined by over 58% during the 59 years reviewed.


Toxoplasma gondii infection is moderately prevalent in Nigeria. Highest prevalence estimates were observed among pregnant women and in the south-south region. For effective control of the disease in Nigeria, a holistic approach involving on-farm, environmental, public health and animal components are suggested.

Peer Review reports


Toxoplasma gondii is an obligate intracellular protozoan zoonotic pathogen of almost all warm-blooded animals including humans and birds [1]. The infection is worldwide in distribution and over 70% of the worlds’ population is infected [2, 3]. Domestic cats are the definitive hosts, and represent the main source of infection through oocysts passed in their faeces. The pathogen is currently a global problem which is present in every country of the world [4].

Human infection may result via several routes including contact with infected cats, the consumption of animal tissues infected by cysts of T. gondii, the ingestion of food or water contaminated with oocysts excreted in the faeces of cats, blood transfusion and intrauterine [5,6,7]. Transmission is influenced by factors such as environmental conditions, host immune status, cultural behaviour, individual’s hygienic practices, type of food and cooking methods [8, 9].

In immunocompetent individuals, Toxoplasma infection may be asymptomatic or self-limiting. However, immunocompromised conditions like HIV infection may alter the clinical course of T. gondii infection [10, 11]. HIV infection may cause reactivation of the asymptomatic Toxoplasma infection resulting in neurological signs like headache, disorientation, drowsiness, hemiparesis, reflex changes and convulsion [12,13,14]. About 25–50% of HIV immunocompromised individuals may show the signs of cerebral toxoplasmosis [15] and Toxoplasma infection is now a known cause of morbidity and mortality in people living with HIV and AIDS (PLWHA) [12].

Toxoplasma induced neonatal complications especially during third trimester of pregnancy may include miscarriage, chorioretinitis, hydrocephalus, cerebral calcification and foetal death [16, 17]. The risk of transmission of Toxoplasma infection from mother to child intrauterine is increased during the third trimester of pregnancy [18, 19]. Continental prevalence of T. gondii across the world ranged between 4.3–75.0% in Africa [20,21,22,23], 14.0–96.3% in Asia [24,25,26], 6.8–51.8% in Europe [27,28,29], 10.6–13.0% in North America [30,31,32] and 26.3–80.0% in South America [33,34,35].

Despite the association of toxoplasmosis with immunocompromised conditions and the increasing number of PLWHA and pregnant women in Nigeria, the nationwide prevalence and burden of T. gondii infection are poorly understood. In this study, we reported the burden of T. gondii infections among normal individuals, HIV patients and pregnant women in Nigeria. It is envisaged that the present finding will enable stakeholders and policy makers in the health sector to re-strategize on the control of toxoplasmosis, thus reducing the burden of the disease especially in Nigerian pregnant women.


Study protocol and literature search procedure

We conducted a systematic review and meta-analysis using the guidelines provided by Moher [36] for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Inclusion of data for quantitative synthesis was based on the PRISMA checklist (Additional file 1), and the infection of humans with Toxoplasma gondii was the outcome of interest. The review protocol was registered on PROSPERO International prospective register of systematic reviews with registration number CRD42019135416 and available from:

Six electronic databases: African Journals OnLine (AJOL), Google Scholar, PubMed, Scopus, Science Direct and Web of Science were systematically searched between 1st June and 30th April 2020 for literature published on T. gondii infection in humans in Nigeria between 1960 and 2019. Additional studies were obtained through searching of list of references of retrieved studies and by contacting editors of Nigerian biomedical journals. Full articles with only visible online abstracts were requested from authors and editors of the publishing journals through phone calls or e-mails. The MeSH search string employed in PubMed was “toxoplasmosis” OR “Toxoplasma” OR “Toxoplasma gondii” OR “Toxoplasma infections” AND “Prevalence” OR “Seroprevalence” OR “Seroepidemiology” AND “Humans” OR “Healthy individuals” OR “HIV patients” OR “Pregnant women” AND “North-central” OR “North-eastern” OR “North-western” Or “South-eastern” OR “South-south” OR “South-western” AND “Nigeria”. Search on AJOL was carried out on journal by journal bases within biomedical journals indexed in the database. Due to the large volume of data in Google Scholar, the study customised article search in this database based on year of publication for ease of sorting articles.

Requirements for inclusion

Studies were subjected to two stages of screening for either inclusion or exclusion. In the first stage, studies were screened by scanning through titles for exclusion of duplicates. Second stage screening involved detailed review of abstract and full text for removal of irrelevant studies and identification of relevant information. A study was considered for inclusion if it had the following characteristics: (i) it was carried out in Nigeria, (ii) it was published in English, (iii) it was carried out and published between January 1960 and December 2019, (iv) it was a cross sectional or prevalence study, (v) it stated the study location, (vi) it clearly stated the number of sample size and positive cases, (vii) it reported T. gondii in humans, and (viii) it stated the target population. Studies that did not meet these inclusion criteria and all unpublished articles were excluded.

Quality assessment

The quality of each article analysed was assessed independently using the 9 point Joanna Briggs Institute (JBI) critical appraisal instrument for studies reporting prevalence data [37]. The JBI checklist posed nine questions viz.: (1) Was the sample frame appropriate to address the target population? (2) Were study participants recruited in an appropriate way? (3) Was the sample size adequate? (4) Were the study subjects and setting described in detail? (5) Was data analysis conducted with sufficient coverage of the identified sample? (6) Were valid methods used for the identification of the condition? (7) Was the condition measured in a standard, reliable way for all participants? (8) Was there appropriate statistical analysis? (9) Was the response rate adequate, and if not, was the low response rate managed appropriately (Additional file 2)? Answers to the aforementioned questions for individual studies were respectively assigned scores of 0 or 1 for no or yes answers, while U or NA were used when a study does not clearly answer the question or when the question was not applicable to the study. For a study to be included in the quantitative synthesis, it was required to have a minimum quality assessment score of 6 (66.7%); that is answering yes to at least 6 of the 9 questions on the checklist.

Extraction of data

To ensure data validation and increase the likelihood of detecting errors, literature search, screening of articles, selection of articles for eligibility and data extraction were performed by both authors (SNK and MNK) independently. However, in cases of discrepancies, both authors crosschecked data simultaneously and discussed issues until consensus was reached. Data pulled out from each published study were name of author, the year the study was carried out, the year it was published, sample size, number of positive cases, study location, study design, method of diagnosis, diagnostic target and characteristics of study population. Where specified, the gender and ages of study population were also extracted and individuals within the age brackets ≤17 years of age were categorised as children while those ≥18 years of age were categorised as adults. Where the study year for any article was not stated, the year preceding its publication year was considered as the year it was conducted.

In our PICOS, we answered questions such as: (1) What is the burden of Toxoplasma gondii infection in normal individuals, HIV patients and pregnant women from Nigeria? (2) Is the burden greater among immunocompromised than normal individuals? (3) What is the distribution pattern of the infection across Nigeria? For the purpose of the present study, an individual was said to be infected with T. gondii only if the individual tested positive for the parasite by microscopic, serological or molecular techniques, normal individuals refers to individuals without any history of pregnancy or any immunocompromised conditions like HIV/AIDS and neoplasia, pregnancy refers to a state where a woman carried an embryo or foetus for a period of ±9 months and HIV patients refer to people living with HIV/AIDS. More so, for the purpose of our analysis, diagnostic methods like polymerase chain reaction (PCR) and immunochromatography which were utilized by only one study, latex agglutination test (LAT) which was utilized by only two studies and studies with unidentified methods of diagnosis were grouped as others.

Data collation and analyses

Preliminary analyses including summations, subtractions, divisions, multiplications and estimation of percentages were conducted using Microsoft Excel. Statistical and meta-analyses were carried out using Graph-Pad Prism version 4.0 and Comprehensive Meta-Analysis version 3.0 respectively. Prevalence of individual studies was determined by expressing the proportion of positive cases of T. gondii infection and sample size as percentages.

Pooling, sub-group and heterogeneity analyses

Pooled prevalence and their 95% Confidence Interval (CI) were estimated by the random-effects model [38]. Sub-group analyses were performed based on ages (Adult, children), gender (female, male), characteristics of study population (normal individuals, HIV patients and pregnant women) and geographic regions (North-central, north-east, north-west, south-east, south-south and south-west). Others were diagnostic methods (Dye test, ELISA, HAT, LAT, PCR, and RSAT), study period (1960–1975, 1976–1990, 1991–2005 and 2006–2019) as well as sample size (≤ 150, 151–300, 301–450 and > 450).

Heterogeneity among studies was evaluated using the Cochran’s Q-test while the percentage variation among studies due to heterogeneity was quantified using the formula I2 = 100 × (Q-df)/Q; where Q is Cochran’s heterogeneity statistic and df is the degree of freedom which is determined by subtracting one from the number of studies analysed. I-square values of 0, 25, 50 and 75% were considered no, low, moderate and substantive heterogeneities respectively [39, 40].

Publication bias, sensitivity and meta-regression analyses

Publication bias (across-study bias) was examined by funnel plots while the statistical significance was assessed by the Egger’s regression asymmetry test [41]. The unbiased estimates were calculated using the Duval and Tweedie non-parametric ‘fill and trim’ linear random method [42]. The robustness of a pooled estimate was tested by the single study omission analysis, and a study was considered to have no influence on the pooled prevalence if the pooled estimate without it (i.e number of studies = 49) was within the 95% confidence limits of the overall pooled prevalence when number of studies equals 50 [43]. Meta-regression analysis was performed for different sub-groups including year of conduct of study, diagnostic methods, geographic regions as well as age, gender and characteristics of the study population to determine the possible sources of heterogeneity.


Literature search and eligible studies

The procedure for selection of eligible studies is presented in Fig. 1. A total of 79 studies resulted from the search of six electronic databases. Twenty five of the studies were duplicates and were removed after screening of titles. Fifty four of the studies were subjected to detailed review of abstract and full text. Four studies were thereafter removed for insufficiency of data on sample sizes and number of cases (n = 3) and lack of information on study location (n = 1). Fifty studies were subjected to the quantitative synthesis. None of the studies assessed for quality by the JBI critical appraisal instrument was excluded for lack of merit. Quality scores ranged between 6 and 8 (66.67–88.89%) of a total of 9 scores (Table 1 and Additional file 3).

Fig. 1
figure 1

Flow diagram for the selection of eligible studies

Table 1 List and characteristics of eligible studies

Characteristics of eligible studies

Table 1 shows the characteristics of the eligible studies. Fifty studies examined 16,230 individuals for Toxoplasma gondii infection among Nigerians and reported prevalence rates ranging between 2.00 and 88.24%. Nine, 4, 10, 8 and 19 of the studies were reported in the north-central, north-eastern, north-western, south-south and the south-western regions respectively. Three studies utilized rapid slide agglutination test (RSAT) for diagnosis, 4 each were diagnosed using dye and haemagglutination tests, 28 of the studies utilized enzyme linked immunosorbent assay (ELISA) while 11 studies utilized other methods (immunochromatographic test 1, LAT 2, PCR 1 and unidentified tests 7). One study each targeted Toxoplasma-immunoglobulin M (IgM) and deoxyribonucleic acid (DNA), 20 studies targeted Toxoplasma-immunoglobulin G (IgG), 17 targeted both IgG and IgM, while 11 studies failed to state their diagnostic targets. Two studies were reported between 1960 and 1975, 6 between 1976 and 1990, 5 between 1991 and 2005 and 37 between 2006 and 2019. Twelve, 18, 13 and 7 of the studies had sample sizes of ≤150, 151–300, 301–450 and > 450 respectively.

Spatial distribution of eligible studies

The 50 studies were reported across 5 of the 6 regions of Nigeria as presented in Fig. 2. The nine (18.00%) studies reported across the north-central region were distributed as follow: one each in Kwara and Niger States, 2 each in Abuja and Benue State, and 3 in Plateau State. Four (8.00%) studies were reported in Borno State, North-east Nigeria while the 10 (20.00%) studies reported across the north-west region were from Kaduna and Sokoto (3 studies each) and 4 from Kano. One study each was reported from Akwa Ibom and Delta States and 3 each from Edo and Rivers States totally 8 (16.00%) studies from the south-south while the 19 (38.00%) studies distributed across the south-west; 1, 2, 6 and 10 were from Ogun, Osun, Oyo and Lagos States respectively. No study was reported in the south-east region.

Fig. 2
figure 2

Regional prevalence of T. gondii and distribution of eligible studies in Nigeria

Pooled prevalence and heterogeneity analysis

Pooled prevalence and heterogeneities are presented in Tables 2 and 3 as well as Figs. 3 and 4. Fifty studies reported 5834 positive cases of Toxoplasma gondii infection among 16,230 individuals examined from 17 Nigerian States. Overall PP was 32.92% (95% CI: 27.89, 38.37; Q-p < 0.001) with ranges of 28.58 (95% CI: 16.28, 45.17; Q-p < 0.001) to 41.00% (95% CI: 25.61, 58.37; Q-p < 0.001) across geographic regions, 14.41% (95% CI: 5.32, 33.54; Q-p < 0.001) to 74.29% (95% CI: 57.49, 86.06; Q-p < 0.001) across methods of diagnosis, 28.75 (95% CI: 23.44, 34.71; Q-p < 0.001) to 86.82% (95% CI: 66.13, 95.69; Q-p: 0.760) across study periods and 30.22 (95% CI: 19.87–43.07; Q-p < 0.001) to 36.64% (95% CI: 24.15, 51.23; Q-p < 0.001) across sample size.

Table 2 Pooled prevalence of T. gondii infection in humans in Nigeria based of sub-groups
Table 3 Pooled prevalence of Toxoplasma gondii infections in relation to age, gender and characteristics of study population
Fig. 3
figure 3

Forest plot for the prevalence of Toxoplasma gondii infection in northern Nigeria

Fig. 4
figure 4

Forest plot for the prevalence of Toxoplasma gondii infection in southern Nigeria

Pooled prevalence of T. gondii infection among adults and children were 36.93% (95% CI: 29.04, 45.59; Q-p < 0.001) and 18.52% (95% CI: 6.02, 44.63; Q-p < 0.001) respectively. Gender-based PP were 30.61% (95% CI: 22.95, 39.51; Q-p < 0.001) and 31.85% (95% CI: 21.79, 43.94; Q-p < 0.001) for females and males respectively. Pooled prevalence reported in both HIV-patients 31.68% (95% CI: 20.53, 45.41; Q-p < 0.001) and pregnant women 40.25% (95% CI: 33.19, 47.73; Q-p < 0.001) were significantly higher (p < 0.001) than that among normal individuals 23.32% (95% CI: 17.25, 30.75; Q-p: 0.001). Overall heterogeneity was 97.64% with a range of 85.76 to 99.17% (Tables 2 and 3).

Publication bias, sensitivity and meta-regression analyses

The funnel plots (Fig. 5) and their respective bias coefficients for studies published in Nigeria as a whole (b: -3.48; 95% CI: − 7.53, 0.58; p: 0.091), northern (b: -3.10; 95% CI: − 7.90, 1.71; p: 0.194) and southern regions (b: -5.03; 95% CI: − 11.05, 0.99; p: 0.098) suggest insignificant publication bias. No outlying study capable of causing publication bias was identified and removed by the Duval and Tweedie’s trim and fill method (Additional file 4). As in Additional file 5, the sensitivity tests showed that all single-study omission estimates were within the 95% CI of the overall PP.

Fig. 5
figure 5

Funnel plots of standard error by logit event rate for pooled prevalence of T. gondii in a Nigeria, b northern Nigeria and c southern Nigeria

Meta-regression analysis (Tables 2 and 3) suggests that geographic regions (Q: 1.89; df: 4; p: 0.756), sample size (Q: 0.53; df: 3; p: 0.913), age (Q: 0.57; df: 1; p: 0.451) and gender of participants (Q: 0.04; df: 1; p: 0.835) were unlikely to be the sources of heterogeneity in the present analysis. However, the year of conduct of the studies (Q: 13.72; df: 3; p: 0.003), methods of diagnosis employed by the studies (Q: 20.65; df: 4; p < 0.001) and characteristics of study population (Q: 6.00; df: 2; p: 0.034) might be the possible causes of the heterogeneity in our analysis.


Adequate understanding of the nationwide burden of toxoplasmosis is essential for effective prevention and control of the disease and its associated complications in immunocompromised individuals. Here, data from individual surveillance studies were harmonised across Nigeria with the sole aim of providing epidemiological information that may serve as a guide for disease monitoring and control in Nigeria.

We observed an overall PP of 32.92% which is consistent with a global report of 34.2% for middle income countries [94]. Our finding is however, higher than the 27.9% reported from Mexico [95] but lower than the 74.7% prevalence reported from Ethiopia [96]. T. gondii infection also showed geographical variations across Nigeria with the highest prevalence observed in the south-south region. Corroborating our finding, geographical variations within countries have been documented elsewhere. For instance, in sub-Saharan Africa, studies from Ethiopia reported prevalence of 68.4, 81.4 and 88.2% in the north-western, central and southern regions respectively [19, 22, 97]. More so, in Asia, studies from China documented prevalence of 8.4, 10.3, 12.3 and 21.6% in Anhui, Shanghai, Jilin and Yunnan provinces respectively [98,99,100,101]. Differences in weather conditions, eating habits, levels of environmental contamination with T. gondii oocysts, personal hygiene and human-cat contacts [96, 102] may be possible explanations for these variations across regions and countries.

The majority of the studies included in the analysis were diagnosed using ELISA. This may be due to the rapidity and accuracy of the method, convenience, ease of use, high sensitivity and specificity, cost effectiveness and the global acceptability of the test [103,104,105]. Studies diagnosed using the dye test recorded the highest disease prevalence probably due to its high specificity and sensitivity [106]. The serological tests conducted by the individual studies analysed targeted IgG (test for convalescent infection), IgM (test for recent or active infections) and their combination. Interestingly, 85% of the studies conducted on pregnant women detected IgM to identify activeness of infection which is a significant decision making stage to ameliorate or prevent congenital consequences based on stage of pregnancy.

The study showed over 58% decline in the PP of T. gondii in Nigeria during the 59 years under review (1960–2019). The decline in recent years could have resulted from controlled movement of cats, improved living standards, life styles and feeding habits that influence the transmission of this pathogen from cats and food animals to man. Other factors that may be responsible for the variations in T. gondii prevalence across study periods may include skills of the researchers involved as well as the sensitivity and specificity of the diagnostic methods employed by the individual studies. The majority of the studies were published within the twenty-first century in agreement with global report on T. gondii [94]. Increased interest on the pathogen arising from its association with severe complications in immunocompromised conditions like HIV infection, neoplasia and pregnancy may be a possible explanation.

The prevalence of T. gondii infection was higher in adults than children concurring reports from Mozambique [107] and Thailand [108]. This may be explained by the habits of eating undercooked roasted meat outside the home and possible intimacy of adults with pet cats. Corroborating a report from China [101], the present study observed a significantly higher prevalence in males than females. Contrary to our finding, Al-Qurashi et al. [7], Domingos et al. [107] and Tegegne et al. [109] reported higher prevalence in females in Saudi Arabia, Mozambique and Ethiopia, respectively.

Prevalence of T. gondii showed substantive heterogeneity among eligible studies reported across Nigeria. Meta-regression analysis suggests that this high heterogeneity might be from sources including years in which the studies were conducted, methods of diagnosis employed by the individual studies, characteristics of the study population and not from study locations, sample sizes, as well as age and gender of participants. The sensitivity tests showed that all single-study omission estimates were within the 95% CI of the overall prevalence, suggesting that the pooled prevalence of T. gondii was not substantially influenced by any single study. No significant publication bias was observed at alpha level of 0.05 with either Egger’s test or Duval and Tweedie’s method. The findings of the publication bias, sensitivity test and meta-regression substantiate the validity and reliability of the present analysis.

The PP of 40.25% observed among Nigerian pregnant women is higher than the range of 6.1–25.0% reported in countries like China [102, 110], Thailand [108] and Mexico [111]. The high prevalence among pregnant women is of major concern particularly in the ability of T. gondii to undergo intrauterine transmission and induce neonatal complications such as miscarriage, chorioretinitis, hydrocephalus, cerebral calcification and foetal death during pregnancy [16, 17]. T. gondii PP in HIV-patients in Nigeria was 31.68% concurring with reports of 36.3 and 38.0% from Thailand [112] and South Africa [113] respectively. The present finding is however; grossly lower than reports of 87.45% [17] and 90.0% [114] from Ethiopia. Another major concern with this finding is the risk of HIV changing the asymptomatic course of T. gondii in these individuals to a severe cerebral toxoplasmosis which is manifested by headache, disorientation, drowsiness, hemiparesis, reflex changes and convulsion [12,13,14].

The public health implications of the present finding in a developing country like Nigeria with a collapse primary health care system which is supposed to take care of the health of the rural majority are increased morbidity and associated complications in pregnant women and PLWHA. Two approaches are pertinent to the control of T. gondii in Nigeria. First, reviewing disease control programmes in Nigeria to include staging of pregnancy and IgG avidity test particularly in Toxoplasma-seropositive pregnant women for possible treatment to prevent congenital consequences and the restriction of cat movement. Second, stakeholders in the area of veterinary public health can also ensure on-farm good agricultural practices as well as standardized veterinary meat inspection to curtail the zoonotic transmission of this pathogen from companion and food animals to man.

The present study has several limitations despite its contribution to knowledge. We could not include some potentially relevant studies which would have added to the understanding of T. gondii infection in Nigeria due to insufficiency of data. A whole region (south-east) was not represented in the analysis because no study was published from the region. Studies analysed were published from only 17 of the 36 States in Nigeria including the Federal Capital Territory and were concentrated in the south-west (n = 19). Over 95% of the studies included in the analysis relied on serological methods of diagnosis which are unreliable in immunocompromised people [42]. This suggests a possible underestimation of the PP reported by the present study in immunocompromised people in Nigeria. The substantive heterogeneity observed among studies indicates variations across studies which could be due to several factors including year of conduct of study, methods of diagnosis and characteristics of study population. This suggests that the present finding may not represent an absolute T. gondii situation in Nigeria, but may provide a guide for disease control policies and the direction for future studies.


T. gondii is moderately prevalent in Nigeria especially in the south-south region and among pregnant women and HIV-patients. The study showed over 58% decline in the PP of T. gondii during the 59 years reviewed (1960–2019). Age was a determining factor in the prevalence of T. gondii infection in Nigeria. To effectively control the disease, a holistic approach involving on-farm, environmental, public health and animal components are suggested.

Availability of data and materials

The data supporting the conclusion of this article are all included in the article and Additional files 1-5.



Acquired immunodeficiency virus


African Journals OnLine


Confidence interval

df :

degree of freedom


Enzyme linked immunosorbent assay


Haemagglutination test


Human immunodeficiency virus


Immunochromatographic test

I 2 :

Inverse variance index


Latex agglutination test


Method of diagnosis


Polymerase chain reaction


People living with HIV/AIDS


Pooled prevalence




Preferred Reporting System for Systematic Reviews and Meta-Analyses


Cochran’s heterogeneity statistic


Cochran’s p-value


Rapid slide agglutination test


  1. 1.

    Dubey JP. Toxoplasmosis of animals and humans. 2nd ed. Boca Raton: CRC Press; 2010.

    Google Scholar 

  2. 2.

    Paul RT, Pierpaolo M. The global burden of congenital toxoplasmosis: a systematic review. Bull Wld Hlth Organ. 2013;91:501–8.

    Google Scholar 

  3. 3.

    Doudou Y, Renaud P, Coralie L, Jacqueline F, Hypolite S, Hypolite M, et al. Toxoplasmosis among pregnant women: high seroprevalence and risk factors in Kinshasa, Democratic Republic of Congo. Asian Pac J Trop Biomed. 2014;4:69–74.

    Article  PubMed  Google Scholar 

  4. 4.

    Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol. 2009;39:1385–94

    PubMed  Article  Google Scholar 

  5. 5.

    Al-Karmi T, Behbehani K. Epidemiology of toxoplasmosis in Kuwait. II. Toxoplasma gondii in the desert rodent Meriones crassus. Tran R Soc Trop Med Hyg. 1980;74:745–6.

    CAS  Article  Google Scholar 

  6. 6.

    Abbas SA, Basalamah A, Serebour F, Alfonso M. The prevalence of Toxoplasma gondii antibodies in Saudi women and the outcome of congenital infection among new-borns in Saudi Arabia. Saudi Med J. 1986;7:346–54.

    Google Scholar 

  7. 7.

    Al-Qurashi AR, Ghandour AM, Obied OE, Al-Mulhim A, Makki SM. Sero-epidemiological study of Toxoplasma gondii infection in the human population in the eastern region. Saudi Med J. 2001;22(1):13–8.

    CAS  PubMed  Google Scholar 

  8. 8.

    Dabritz HA, Conrad PA. Cats and Toxoplasma: implications for public health. Zoon Pub Hlth. 2010;57:34–52.

    CAS  Article  Google Scholar 

  9. 9.

    Caballero-Ortega H, Uribe-Salas FJ, Conde-Glez CJ, Cedillo-Pelaez C, Vargas-Villavicencio JA, Luna-Pastén H, et al. Sero-prevalence and national distribution of human toxoplasmosis in Mexico: analysis of the 2000 and 2006 national health surveys. Tran R Soc Trop Med Hyg. 2012;106(11):653–9.

    Article  Google Scholar 

  10. 10.

    Welker Y, Molina JM, Poirot C, Ferchal F, Decazes JM, Lagrange P, et al. Interaction between human immunodeficiency virus and Toxoplasma gondii replication in dually infected monocytoid cells. Infect Immun. 1993;61(4):1596–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Bala S, Englund G, Kovacs J, Wahl L, Martin M, Sher A, et al. Toxoplasma gondii soluble products induce cytokine secretion by macrophages and potentiate in vitro replication of a monotropic strain of HIV. J Eukaryot Microbiol. 1994;41:7S.

    CAS  PubMed  Google Scholar 

  12. 12.

    Barratt JL, Harkness J, Marriott D, Ellis JT, Stark D. Importance of non-enteric protozoan infections in immunocompromised people. Clin Microbiol Rev. 2010;23:795–836.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264–96.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Machala L, Kodym P, Maly M, Geleneky M, Beran O, Jilich D. Toxoplasmosis in immunocompromised patients. Epidemiol Mikrobiol Imunol. 2015;64:59–65.

    CAS  PubMed  Google Scholar 

  15. 15.

    Alonso R, Heiman-Patterson T, Mancall EL. Cerebral toxoplasmosis in acquired immune deficiency syndrome. Arch Neurol. 1984;41:321–3.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Torgerson PR, Macpherson CN. The socioeconomic burden of parasitic zoonoses: global trends. Vet Parasitol. 2011;182(1):79–95.

    Article  PubMed  Google Scholar 

  17. 17.

    Walle F, Kebede N, Tsegaye A, Kassa T. Sero-prevalence and risk factors for Toxoplasmosis in HIV infected and non-infected individuals in Bahir Dar, Northwest Ethiopia. Parasit Vectors. 2013;6(15):8

    Google Scholar 

  18. 18.

    Bessieres MH, Berrebi A, Cassaing S, Fillaux J, Cambus JP, Berry A, et al. Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. Mem Inst Oswaldo Cruz. 2009;104(2):389–92.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Gebremedhin EZ, Abebe AH, Tessema TS, Tullu KD, Medhin G, Vitale M, et al. Sero-epidemiology of Toxoplasma gondii infection in women of child-bearing age in central Ethiopia. BMC Infect Dis. 2013;13(101):6.

    CAS  Article  Google Scholar 

  20. 20.

    Zumla A, Savva B, Wheeler RB, Hira SK, Luo NP, Kaleebu P, et al. Toxoplasma serology in Zambian and Ugandan patients infected with the human immunodeficiency virus. Tran R Soc Trop Med Hyg. 1991;85(2):227–9.

    CAS  Article  Google Scholar 

  21. 21.

    Khalil KM, Ahmed AA, Elrayah LE. Sero-prevalence of Toxoplasma gondii infection in humans in Khartoum state, Sudan. Intern J Trop Med. 2012;7:143–50.

    Article  Google Scholar 

  22. 22.

    Yohanes T, Debalke S, Zemene E. Latent Toxoplasma gondii infection and associated risk factors among HIV-infected individuals at Arba Minch hospital. South Ethiopia AIDS Res Treat. 2014;2014:6.

    Article  Google Scholar 

  23. 23.

    Mirambo MM, Mushi MF, Kivambe C. High sero-prevalence of specific Toxoplasma gondii IgG antibodies among HIV/AIDS patients with immunological failure attending a tertiary hospital in North-Western Tanzania. Tanz J Hlth Res. 2016;18:1–4.

    Google Scholar 

  24. 24.

    Hagiwara E, Ito A, Shirai A, Kawada K, Okubo T, Amano T, et al. Seroprevalence of anti-Toxoplasma IgG antibody in Japanese patients with HIV infection. Kansenshogaku Zasshi. 2001;75:703–4.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Rostami A, Keshavarz H, Shojaee S, Mohebali M, Meamar AR. Frequency of Toxoplasma gondii in HIV positive patients from west of Iran by ELISA and PCR. Iran J Parasitol. 2014;9:474–81.

    PubMed  PubMed Central  Google Scholar 

  26. 26.

    Rahimi MT, Mahdavi SA, Javadian B, Javadian B, Rezaei R, Moosazadeh M, et al. High sero-prevalence of Toxoplasma gondii antibody in HIV/AIDS individuals from north of Iran. Iran J Parasitol. 2015;10:584–9.

    PubMed  PubMed Central  Google Scholar 

  27. 27.

    Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988–1995. Clin Infect Dis. 1999;28:575–81.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Đaković-Rode O, Židovec-Lepej S, Vodnica-Martucci M, Lasica PV, Begovac J. Prevalence of antibodies against Toxoplasma gondii in patients infected with human immunodeficiency virus in Croatia. Infektol Glas. 2010;30:5–10.

    Google Scholar 

  29. 29.

    Llenas-García J, Rubio R, Hernando A, Fiorante S, Maseda D, Matarranz M, et al. Clinico-epidemiological characteristics of HIV positive immigrants: study of 371 cases. Enferm Infecc Microbiol Clin. 2012;30(8):441–51.

    Article  PubMed  Google Scholar 

  30. 30.

    Johns DG, Gill MJ. Sero-prevalence of cytomegalovirus, Toxoplasma gondii, syphilis, and hepatitis B and C virus infections in a regional population seropositive for HIV infection. Can J Infect Dis. 1998;9:209–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Falusi O, French AL, Seaberg EC, Tien PC, Watts DH, Minkoff H, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis. 2002;35(11):1414–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    O’Bryan TA, Okulicz JF, Bradley WP, Ganesan A, Merritt SE, Agan BK. Toxoplasma gondii sero-prevalence: 30-year trend in an HIV-infected US military cohort. Diagn Microbiol Infect Dis. 2016;84:34–5.

    PubMed  Article  Google Scholar 

  33. 33.

    Pérez CC, Cerón AI, Fuentes LG, Zañartu SC, Balcells MME, Ajenjo HC, et al. Hepatitis B, C, Treponema pallidum and Toxoplasma gondii co-infections in HIV infected patients. Rev Med Chil. 2009;137:641–8.

    Google Scholar 

  34. 34.

    Vidal JE, Diaz AV, de Oliveira AC, Dauar RF, Colombo FA. Pereira-Chioccola VL Importance of high IgG anti-Toxoplasma gondii titers and PCR detection of T gondii DNA in peripheral blood samples for the diagnosis of AIDS-related cerebral toxoplasmosis: a case-control study. Braz J Infect Dis. 2011;15:356–9.

    PubMed  Google Scholar 

  35. 35.

    Xavier GA, Cademartori BG, Cunha FNA, Farias NA. Evaluation of sero-epidemiological toxoplasmosis in HIV/AIDS patients in the south of Brazil. Rev Inst Med Trop Sao Paulo. 2013;55:25–30.

    PubMed  Article  Google Scholar 

  36. 36.

    Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data. Int J Evid Based Healthc. 2015;13:147–53.

    PubMed  Article  Google Scholar 

  38. 38.

    Hedges LV, Vevea JL. Fixed- and random-effects models in meta-analysis. Psychol Meth. 1998;3:486–504.

    Article  Google Scholar 

  39. 39.

    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Meth. 2002;21:1539–58.

    Google Scholar 

  40. 40.

    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315:629–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Gao L, Zhang L, Jin Q. Meta-analysis: prevalence of HIV infection and syphilis among MSM in China. Sex Transm Infect. 2009;85:354–8.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Adeniyi OT, Adekola SS, Oladipo OM. Sero-epidemiology of toxoplasmosis among pregnant women in Osogbo, southwestern, Nigeria. J Infect Dis Immun. 2018;10(2):8–16.

    Google Scholar 

  45. 45.

    Adepoju FG, Olawumi HO, Adekoya BJ. HIV sero-positivity and related eye diseases in UITH, Ilorin. Niger Postgrad Med J. 2007;14(2):163–5.

    CAS  PubMed  Google Scholar 

  46. 46.

    Aganga AO, Umoh JU, Ekwempu CC. Seroprevalence studies of human Toxoplasma infection in Zaria, Nigeria. Nig J Parasitol. 1990;11:159–64.

    Google Scholar 

  47. 47.

    Akanmu AS, Osunkalu VO, Ofomah JN, Olowoselu FO. Pattern of demographic risk factors in the seroprevalence of anti-Toxoplasma gondii antibodies in HIV infected patients at the Lagos University teaching hospital. Nig Quart J Hosp Med. 2010;20(1):1–4.

    CAS  Article  Google Scholar 

  48. 48.

    Akinbami AA, Adewunmi AA, Rabiu KA, Wright KO, Dosunmu AO, Dada MO, et al. Seroprevalence of Toxoplasma gondii antibodies amongst pregnant women at the Lagos State University teaching hospital, Nigeria. Niger Postgrad Med J. 2010;17(2):164–7.

    CAS  PubMed  Google Scholar 

  49. 49.

    Alayande MO, Edungbola LD, Fabiyi JP, Awosan KI, Babatunde SK, Suleiman AI, et al. Seroprevalence of Toxoplasma infection in stored sera of HIV individual in Sokoto, Nigeria. Afr J Microbiol Res. 2012a;6(5):972–5.

    Article  Google Scholar 

  50. 50.

    Alayande MO, Edungbola LD, Fabiyi JP, Faleke OO, Awosan KJ, Fadeyi A, et al. Sero-prevalence of Toxoplasma gondii infection among abattoir workers in Sokoto, Nigeria. Sahel Med J. 2012b;15:80–4.

    Google Scholar 

  51. 51.

    Alayande MO, Edungbola LD, Fabiyi JP, Awosan KJ. Occurrence of antibody to Toxoplasma infection among pregnant women with obstetric histories and at different trimesters in Sokoto, Northwest Nigeria. Am J Res Comm. 2013;1(9):240–7.

    Google Scholar 

  52. 52.

    Amoo A, Njaanake K, Dada-Adegbola HO, Omosa-Manyonyi G. Toxoplasmosis among blood donors: unsafe blood transfusion in Ibadan, Southwest Nigeria. J Appl Hematol. 2019;10:120–5.

    Article  Google Scholar 

  53. 53.

    Amuta EU, Amali O, Jacob SE, Houmsou RS. Toxoplasma gondii IgG antibodies in HIV/AIDS patients attending hospitals in Makurdi metropolis, Benue state, Nigeria. Intern J Med Biomed Res. 2012;1(3):186–92.

    Article  Google Scholar 

  54. 54.

    Arene FOI. The prevalence of toxoplasmosis among inhabitants of the Niger Delta. Folia Parasitol. 1986;33:311–4.

    CAS  PubMed  Google Scholar 

  55. 55.

    Awobode HO, Olubi IC. Prevalence of Toxoplasma gondii and HIV infection among pregnant women in Ibadan north local government, Oyo state. Afr J Med Medical Sci. 2014;43:39–45.

    Google Scholar 

  56. 56.

    Bata SI, Ajogi I, Umoh JU, Lawal I, Randawa AJ. Sero-prevalence and risk factors for Toxoplasma gondii infection among antenatal women in Zaria, Nigeria. Res J Med Medical Sci. 2009;4(2):483–8.

    Google Scholar 

  57. 57.

    Deji-Agboola AM, Busari OS, Osinupebi OA, Amoo AOJ. Sero-prevalence of Toxoplasma gondii antibodies among pregnant women attending antenatal clinic of the Federal Medical Centre, Lagos, Nigeria. Intern J Biol Med Res. 2011;2(4):1135–9.

    Google Scholar 

  58. 58.

    Ekanem US, Moses AE, Abraham EG, Motilewa OO, Umo AN, Uwah AI, Itina EI. Seroprevalence of anti-Toxoplasma gondii IgG antibody and risk factors among abattoir workers in Uyo, southern Nigeria. Niger J Clin Pract. 2018;21:1662–9.

    CAS  PubMed  Google Scholar 

  59. 59.

    Ekweozor CC, Okpala LE, Bamgboye AE, Jegede O. Toxoplasmosis: anti-Toxoplasma IgG antibody levels in patients with lymphoid neoplasia in Ibadan, Nigeria. Afr J Med Medical Sci. 1994;23(4):347–53.

    CAS  Google Scholar 

  60. 60.

    Enitan SS, Adejumo AO, Oluremi AS, Ileoma E, Adejumo EN, Oyedele TF, Enitan CB. Sero-prevalence of anti-toxoplasma Gondii IgM and IgG antibodies among young adults with history of ocular infection in South-Western Nigeria. EAS J Parasitol Infect Dis. 2019;1(6):133–43.

    Google Scholar 

  61. 61.

    Goni BW, Bakki B, Kida IM, Yusuph H, Zailani SB, Mustapha SK, et al. Sero-prevalence of IgG anti-T. gondii antibody among HIV infected patients in Maiduguri, north eastern Nigeria. J Med Sci. 2012;6:7–14.

    Google Scholar 

  62. 62.

    Gyang VP, Akinwale OP, Lee Y, Chuang T, Orok A, Ajibaye O, et al. Toxoplasma gondii infection: sero-prevalence and associated risk factors among primary schoolchildren in Lagos City, southern Nigeria. Rev da Soc Bras de Med Trop. 2015;48(1):56–63.

    Article  Google Scholar 

  63. 63.

    Ibrahim A, Kumurya AS, Yahaya H, Abdu A, Ado BK, Ella EE, et al. T-cell mediated immune responses in obstetric population acutely infected with toxoplasmosis in Kano, Nigeria. UMYU J Microbiol Res. 2017;2(1):217–27.

    Google Scholar 

  64. 64.

    Iverson HA, Hursh MD, Lewis A. Toxoplasmosis serological studies on patients with chorio-retinitis in Nigeria. Brit J Ophthal. 1960;44:537–40.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    James BO, Agbonile IO, Okolo M, Lawani AO, Omoaregba JO. Prevalence of Toxoplasma gondii infection among individuals with severe mental illness in Nigeria: a case control study. Path Glob Hlth. 2013;107(4):189–93.

    Article  Google Scholar 

  66. 66.

    Kamani J, Mani AU, Egwu GO, Kumshe HA. Sero-prevalence of human infection with Toxoplasma gondii and the associated risk factors, in Maiduguri, Borno state, Nigeria. Ann Trop Med Parasitol. 2009;103(4):317–21.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Mirabeau TY, Ebikade AO. Low sero-prevalence of Toxoplasma gondii IgG and IgM antibodies in HIV sero-positive patients attending National Hospital, Abuja, Nigeria. J Life Sci. 2012;6:481–4.

    Google Scholar 

  68. 68.

    Nasir IA, Aderinsayo AH, Mele HU, Aliyu MM. Prevalence and associated risk factors of Toxoplasma gondii antibodies among pregnant women attending Maiduguri teaching hospital, Nigeria. J Med Sci. 2015;15(3):147–54.

    CAS  Article  Google Scholar 

  69. 69.

    Oboro IL, Obunge OK, Wariso KT. Sero-epidemiology of toxoplasmosis among pregnant women in the University of Port Harcourt Teaching Hospital, Nigeria. Nig Hlth J. 2016;16(1):12.

    Google Scholar 

  70. 70.

    Ogefere HO, Ali AS, Omoregie R. Effect of CD4 count on the prevalence of IgG and IgM anti-toxoplasma antibodies among HIV positive patients in Benin City, Edo state, Nigeria. J Med Lab Sci. 2019;29(3):54–60.

    Google Scholar 

  71. 71.

    Ogoina D, Onyemelukwe GC, Musa BO, Obiako R. Sero-prevalence of IgM and IgG antibodies to Toxoplasma infection in healthy and HIV-positive adults from northern Nigeria. J Infect Dev Ctries. 2013;7(5):398–403.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Okoh AEJ, Agbonlahor DE, Momoh M. Toxoplasmosis in Nigeria- a serological survey. Trop Anim Hlth Prod. 1981;13:137–43.

    CAS  Article  Google Scholar 

  73. 73.

    Okwuzu JO, Odunukwe NN, Ezechi OC, Gbajabiamila TA, Musa AZ, Ezeobi PM, et al. Toxoplasma gondii infection in HIV/AIDS: prevalence and risk factors. Afr J Clin Exp Microbiol. 2014;15(2):97–102

    Article  Google Scholar 

  74. 74.

    Okwuzu JO, Otubanjo AO, Ezechi OC, Idowu ET, Odunukwe NN, Okoye RN, et al. Toxoplasma gondii infection among HAART-naive HIV-positive patients and HIV-negatives in Lagos state, Nigeria. Intern J Microbiol Immunol Res. 2015;3:1–8.

    Google Scholar 

  75. 75.

    Olusi T, Gross U, Ajayi J. High incidence of toxoplasmosis during pregnancy in Nigeria. Scand J Infect Dis. 1996;28(6):645–6.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Onadeko MO, Joynson DH, Payne RA. The prevalence of Toxoplasma infection among pregnant women in Ibadan, Nigeria. J Trop Med Hyg. 1992;95(2):143–5.

    CAS  PubMed  Google Scholar 

  77. 77.

    Onakoya AO, Odeyemi MG, Aribaba OT, Akinsola FB. Ocular findings in acquired immunodeficiency syndrome patients in Lagos, Nigeria. Nig Quart J Hosp Med. 2012;22(1):52–7.

    CAS  Google Scholar 

  78. 78.

    Onosakponome EO, Wokem GN, Abah AE. Comparison of ELISA and Rapid Immunochromatographic tests in diagnosis of toxoplasmosis in Port Harcourt, Nigeria. Intern J Trop Dis. 2020;41(1):54–9.

    Google Scholar 

  79. 79.

    Oshinaike OO, Okubadejo NU, Ojini FI, Danesi MA. A preliminary study of the frequency of focal neurological deficits in HIV/AIDS patients sero-positive for Toxoplasma gondii IgG in Lagos, Nigeria. Nig Quart J Hosp Med. 2010;20(3):104–7.

    CAS  Google Scholar 

  80. 80.

    Osiyemi TIO, Synge EMM, Agbonlaho DE, Agbavwe R. The prevalence of Toxoplasma gondii antibodies in man in plateau state and meat animals in Nigeria. Trans R Soc Trop Med Hyg. 1985;79:21–3.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    Osunkalu VO, Akanmu SA, Ofomah NJ, Onyiaorah IV, Adediran AA, Akinde RO, et al. Sero-prevalence of Toxoplasma gondii IgG antibody in HIV-infected patients at the Lagos University teaching hospital. HIV/AIDS Res Palliative Care. 2011;3:101–5.

    Article  Google Scholar 

  82. 82.

    Oyinloye SO, Igila-Atsibee M, Ajayi B, Lawan MA. Serological screening for ante-natal toxoplasmosis in Maiduguri municipal council, Borno state, Nigeria. Afr J Clin Exp Microbiol. 2014;15(2):91–6.

    Article  Google Scholar 

  83. 83.

    Sanyaolu AO, Oyibo WA, Iriemenam NC, Badaru OS. Sero-prevalence study of parasitic infections among HIV positive and negative patients in Lagos, Nigeria. Afr J Clin Exp Microbiol. 2016;17(2):88–96.

    Article  Google Scholar 

  84. 84.

    Sixl W, Rosegger H, Schneeweiss H, Withalm H, Schuhmann G. Serological investigations in Nigeria for anthropozoonoses in human sera: brucellosis, echinococcosis, toxoplasmosis, chlamydial diseases, listeriosis, rickettsiosis (Coxiella burneti and Rickettsia conori). J Hyg Epidemiol Microbiol Immunol. 1987;31(4):493–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. 85.

    Sowemimo OA, Wuc T, Leed Y, Asaolua SO, Chuange T, Akinwalef OP, et al. Toxoplasma gondii: sero-prevalence and associated risk factors among preschool-aged children in Osun state, Nigeria. Tran R Soc Trop Med Hyg. 2018;00:1–6.

    Article  Google Scholar 

  86. 86.

    Thomas V, Fabiyi A, Adeniyi A. Prevalence of antibodies to parasitic infections in Nigerian children. J Trop Med Hyg. 1981;84(3):113–6.

    CAS  PubMed  Google Scholar 

  87. 87.

    Uneke CJ, Duhlinska DD, Njoku MO, Ngwu BAF. Sero-prevalence of acquired toxoplasmosis in HIV-infected and apparently healthy individuals in Jos, Nigeria. Parasitol. 2005;47:233–6.

    CAS  Google Scholar 

  88. 88.

    Uneke CJ, Duhlinska DD, Ngwu BA, Njoku MO. Sero-prevalence of Toxoplasma gondii infection in Kwal, a rural district of plateau-Nigeria. Afr J Med Medical Sci. 2007;36(2):109–13.

    CAS  Google Scholar 

  89. 89.

    Uttah EC, Ajang R, Ogbeche J, Etta H, Etim L. Comparative sero-prevalence and risk factors of toxoplasmosis among three subgroups in Nigeria. J Natural Sci Res. 2013;3(8):23–8.

    Google Scholar 

  90. 90.

    Wiseman RA, Woodruff AW. Toxoplasmal and toxocaral infections: a clinical investigation into their relationship. Brit Med J. 1970;4:152–3.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Wokem GN, Onosakponome E, Arene FOI. Sero-prevalence of toxoplasmosis and associated risk factors among pregnant women attending antenatal clinic in the University of Port Harcourt Teaching Hospital, Rivers state, Nigeria Nig J Parasitol 2018;39(1): 98–102.

  92. 92.

    Yusuf AM, Yahaya S, Azeez-Akande O. Sero-prevalence and risk factors of Toxoplasma gondii infection (toxoplasmosis) among HIV seropositive pregnant women in a tertiary healthcare centre, Kano, Northern Nigeria. J Med Medical Sci. 2016;7(1):001–5.

    Article  Google Scholar 

  93. 93.

    Yusuf E, Airauhi LU. Sero-prevalence of Toxoplasma gondii among HIV patients in University of Benin Teaching Hospital (UBTH), Benin City, Edo state. Nigeria Borno Med J. 2017;14(1):78–84.

    Google Scholar 

  94. 94.

    Wang Z, Wang S, Liu H, Ma H, Li Z, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis. Lancet HIV. 2017;4:e177–88.

    Article  PubMed  Google Scholar 

  95. 95.

    Galvan-Ramirez ML, Troyo R, Roman S, Calvillo-Sanchez C, Bernal-Redondo R. A systematic review and meta-analysis of Toxoplasma gondii infection among the Mexican population. Parasit Vectors. 2012;5(271):12.

    Article  Google Scholar 

  96. 96.

    Gebremedhin EZ, Tadesse G. A meta-analysis of the prevalence of Toxoplasma gondii in animals and humans in Ethiopia. Parasit Vectors. 2015;8(291):9.

    Article  Google Scholar 

  97. 97.

    Agmas B, Tesfaye R, Koye DN. Seroprevalence of Toxoplasma gondii infection and associated risk factors among pregnant women in Debre Tabor, Northwest Ethiopia. BMC Res Notes. 2015;8(107):7.

    Article  Google Scholar 

  98. 98.

    Xiao Y, Yin J, Jiang N, Xiang M, Hao L, Lu H, et al. Sero-epidemiology of human Toxoplasma gondii infection in China. BMC Infect Dis. 2010;10(4):5

    Google Scholar 

  99. 99.

    Tao YL, Zhao XT, Fu YF, Tang YF, Li SS, Cheng XJ. Serological survey of Toxoplasma gondii infection among public health practitioners in Xuhui District of Shanghai. Chin J Parasitol Parasit Dis. 2012;30:495–7.

    Google Scholar 

  100. 100.

    Li HL, Dong L, Li Q, Zhang L. Sero-epidemiology of Toxoplasma gondii infection in Bai and Han ethnic groups in South-Western China. Epidemiol Infect. 2015;143(4):881–6.

    CAS  Article  PubMed  Google Scholar 

  101. 101.

    Wang L, He L, Meng D, Chen Z, Wen H, Fang G, et al. Sero-prevalence and genetic characterization of Toxoplasma gondii in cancer patients in Anhui Province, Eastern China. Parasit Vectors. 2015;8(162):7.

    Article  Google Scholar 

  102. 102.

    Liu Q, Wei F, Gao S, Jiang L, Lian H, Yuan B, et al. Toxoplasma gondii infection in pregnant women in China. Tran R Soc Trop Med Hyg. 2009;103(2):162–6.

    Article  Google Scholar 

  103. 103.

    Chen R, Lu S, Lou D, Zeng X, Ding Z, Wen L, et al. Evaluation of a rapid ELISA technique for detection of circulating antigens of Toxoplasma gondii. Microbiol Immun. 2008;52(3):180–7.

    CAS  Article  Google Scholar 

  104. 104.

    Nagaty IM, Ibrahim KM, Abdel-Tawab AH, Hassan AE. Diagnosis of Toxoplasma gondii by ELISA and PCR in mothers and their infants. J Egypt Soc Parasitol. 2009;39(2):625–32.

    PubMed  Google Scholar 

  105. 105.

    Turunen H, Vuorio KA, Leinikki PO. Determination of IgG, IgM and IgA antibody responses in human toxoplasmosis by enzyme-linked immunosorbent assay (ELISA). Scand J Infect Dis. 1983;15:307–11.

    CAS  PubMed  Article  Google Scholar 

  106. 106.

    Reiter-Owona I, Petersen E, Joynson D, Aspöck H, Dardé ML, Disko R, et al. The past and present role of the Sabin-Feldman dye test in the sero-diagnosis of toxoplasmosis. Bull Wld Hlth Organ. 1999;77(11):929–35.

    CAS  Google Scholar 

  107. 107.

    Domingos A, Ito LS, Coelho E, Lucio JM, Matida LH, Ramos AN Jr. Sero-prevalence of Toxoplasma gondii IgG antibody in HIV/AIDS-infected individuals in Maputo, Mozambique. Rev Saude Publica. 2013;47:890–6.

    PubMed  Article  Google Scholar 

  108. 108.

    Andiappan H, Nissapatorn V, Sawangjaroen N, Chemoh W, Lau YL, Kumar T, et al. Toxoplasma infection in pregnant women: a current status in Songklanagarind hospital, southern Thailand. Parasit Vectors. 2014;7(239).

  109. 109.

    Tegegne D, Abdurahaman M, Mosissa T, Yohannes M. Anti-Toxoplasma antibodies prevalence and associated risk factors among HIV patients. Asian Pac J Trop Med. 2016;9(5):460–4

    CAS  PubMed  Article  Google Scholar 

  110. 110.

    Jenum PA, Stray-Pedersen B, Melby KK, Kapperud G, Whitelaw A, Eskild A, et al. Incidence of Toxoplasma gondii infection in 35,940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol. 1998;36(10):2900–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Alvarado-Esquivel C, Sifuentes-Álvarez A, Narro-Duarte SG, Estrada-Martínez S, Díaz-García JH, Liesenfeld O, et al. Sero-epidemiology of Toxoplasma gondii infection in pregnant women in a public hospital in northern Mexico. BMC Infect Dis. 2006:6(113), 7.

  112. 112.

    Cong W, Dong XY, Meng QF, Zhou N, Wang XY, Huang SY, et al. Toxoplasma gondii infection in pregnant women: a sero-prevalence and case-control study in eastern China. Biomed Res Int. 2015;2015:6.

    CAS  Article  Google Scholar 

  113. 113.

    Shimelis T, Tebeje M, Tadesse E, Tegbaru B, Terefe A. Sero-prevalence of latent Toxoplasma gondii infection among HIV-infected and HIV-uninfected people in Addis Ababa, Ethiopia: A comparative cross-sectional study. BMC Res Notes. 2009;2(213):5.

    Article  Google Scholar 

  114. 114.

    Chemoh W, Sawangjaroen N, Siripaitoon P, Andiappan H, Hortiwakul T, Sermwittayawong N, et al. Toxoplasma gondii – prevalence and risk factors in HIV-infected patients from Songklanagarind hospital, Southern Thailand. Fron Microbiol. 2015;6(1304).

Download references


We are grateful to the Editor-In-Chief of Nigerian Journal of Parasitology for providing some of the articles included in the analysis, and to all authors whose articles are included in this study. We also appreciate Mrs. Juliana Tije for assisting in literature search.


Not applicable.

Author information




SNK: Conceived and designed the study, SNK and MNG: conducted literature search, identified articles, screened articles and extracted data. SNK: Conducted statistical and meta-analyses and wrote the manuscript. Both authors read and approved the final manuscript.

Corresponding author

Correspondence to Solomon Ngutor Karshima.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.

Additional file 2.

JBI critical appraisal instrument for studies reporting prevalence data.

Additional file 3.

Quality assessment scores for eligible studies.

Additional file 4.

Results for Egger regression analysis.

Additional file 5.

Results for single study omission analysis.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Karshima, S.N., Karshima, M.N. Human Toxoplasma gondii infection in Nigeria: a systematic review and meta-analysis of data published between 1960 and 2019. BMC Public Health 20, 877 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Geographical distribution
  • HIV patients
  • Normal individuals
  • Pregnant women
  • Prevalence
  • Toxoplasma gondii